LRATD2 and cancer: Consistent with our results, the pan-cancer patients with FAM84BAmp had significantly shorter overall and relapse-free survival compared with the wild type patients (P = 0.0233; P = 7.52e−9, Fig. 2B), suggesting that FAM84B amplification might result in a worse prognosis.